[artículo] 
inThe American Journal of Psychiatry > Año 2021 - Vol. 178 - No.3 (Marzo) . - pp. 256-265

Título :	Ulipristal acetate for treatment of premenstrual dysphoric disorder : a proof-of-concept randomized controlled trial
Tipo de documento:	texto impreso
Autores:	Erika Comasco, Autor ; Helena Kopp Kallner, Autor ; Marie Bixo, Autor
Fecha de publicación:	2021
Artículo en la página:	pp. 256-265
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Trastorno disfórico premenstrual, Neuroendocrinología, Acetato de ulipristal, Progesterona, Modulador selectivo del receptor de progesterona
Resumen:	Premenstrual dysphoric disorder (PMDD) is a common mood disorder, characterized by distressing affective, behavioral, and somatic symptoms in the late luteal phase of the menstrual cycle. The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potential treatment for PMDD.
Link:	./index.php?lvl=notice_display&id=26879

[artículo] Ulipristal acetate for treatment of premenstrual dysphoric disorder : a proof-of-concept randomized controlled trial [texto impreso] / Erika Comasco, Autor ; Helena Kopp Kallner, Autor ; Marie Bixo, Autor . - 2021 . - pp. 256-265.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.3 (Marzo) . - pp. 256-265

Palabras clave:	Trastorno disfórico premenstrual, Neuroendocrinología, Acetato de ulipristal, Progesterona, Modulador selectivo del receptor de progesterona
Resumen:	Premenstrual dysphoric disorder (PMDD) is a common mood disorder, characterized by distressing affective, behavioral, and somatic symptoms in the late luteal phase of the menstrual cycle. The authors investigated continuous treatment with a selective progesterone receptor modulator, ulipristal acetate (UPA), as a potential treatment for PMDD.
Link:	./index.php?lvl=notice_display&id=26879